Merck also known as MSD to countries outside the United States and Canada, and Ridgeback Biotherapeutics today made an important announcement as they signed a long-term supply agreement with (UNICEF). This will allow broad access globally for molnupiravir. Paxlovid is Pfizer’s offering for an orally ingested Covid-19 antiviral medication and this offering from Merck for their oral antiviral COVID-19 medicine will allocate 3 million doses of molnupiravir to UNICEF through to June 2022. With a focus on more than 100 low- and middle-income countries within the regulatory parameters. Molnupiravir has authorization for use in over 10 countries, this includes the United States, United Kingdom, Japan and Taiwan. Merck has been inventing for the preservation of life for over 130 years, bringing forth medications in the pursuit to save lives.
GET A FREE STOCK REPORT
Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.